Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A

6(75.0%)

Phase 2

1(12.5%)

Phase 3

1(12.5%)

8Total

N/A(6)

Phase 2(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT05170984Not ApplicableCompleted

MAtrix Therapy for Hard-to-heal ChrOnic Wounds

Role: lead

NCT06700824Phase 2Not Yet Recruiting

A Trial to Assess the Efficacy and Safety of OTR4132-MD in Patients with Acute Ischemic Stroke

Role: lead

NCT04083001Not ApplicableCompleted

An Open, Study to Assess the Safety of RGTA® (OTR4132) in Patients With Acute Ischemic Stroke (AIS)

Role: lead

NCT05528328Phase 3Recruiting

Post-surgical Scars After the Use of CACIPLIQ20

Role: lead

NCT06007235Not ApplicableRecruiting

CACIPLIQ20 in Wound Healing in Subjects With Epidermolysis Bullosa

Role: lead

NCT01840436Not ApplicableCompleted

Efficacy of MUCIPLIQ on the Incidence of Radio-chemotherapy-induced Mucositis in Patients Suffering From Oral Cancer

Role: lead

NCT01242839Not ApplicableCompleted

Randomized Double Blinded Study Evaluating CACICOL20 Efficiency Versus Placebo Corneal Chronic Ulcers Healing

Role: lead

NCT01474473Not ApplicableCompleted

Efficacy Of CACIPLIQ20 On Diabetic Ulcers In Patients Wearing An Nonremovable, Windowed, Fiberglass Cast Boot

Role: lead

All 8 trials loaded